Abstract
Cancer nanotherapeutics have shown promise in resolving some of the limitations of conventional drug delivery systems such as nonspecific biodistribution and targeting, lack of water solubility, low therapeutic indices, and poor oral bioavailability. Moreover, cancer nanotechnology has the potential of improving current approaches to cancer detection, diagnosis, and imaging. Recently, nanotechnology and molecular imaging have been combined to generate nanoparticles that simultaneously facilitate cancer therapy and diagnosis, the so called theragnostic nanoparticles. The aim of our review is to highlight recent developments within the context of the current knowledge of nanotechnology, to recall the experimental steps that have brought to the clinical development and application of nanoparticles, and explain the biological rationale for their use with oncologic patients. In particular, we summarize recent findings with respect to possible new applications for therapy and diagnosis, and their specific properties. Moreover, we report the more recent prospects in gene therapy, the possibility of using new drug delivery methods, the action of nanoparticles on the immune system and apoptosis, and the concrete possibility of detecting and characterizing circulating tumor cells or of developing new technologies in drug discovery.
Keywords: Drug delivery, gene therapy, imaging, nanoparticles, nanovectors, nanotechnology, theragnostic molecules, chitosan-based nanoparticles (CNPs), polyethylene glycol PEG, Docetaxel, Magnetic drug targeting (MDT)
Anti-Cancer Agents in Medicinal Chemistry
Title: Nanoparticles in Oncology: The New Theragnostic Molecules
Volume: 11 Issue: 7
Author(s): Alessandro Allegra, Giuseppa Penna, Andrea Alonci, Vincenzo Rizzo, Sabina Russo and Caterina Musolino
Affiliation:
Keywords: Drug delivery, gene therapy, imaging, nanoparticles, nanovectors, nanotechnology, theragnostic molecules, chitosan-based nanoparticles (CNPs), polyethylene glycol PEG, Docetaxel, Magnetic drug targeting (MDT)
Abstract: Cancer nanotherapeutics have shown promise in resolving some of the limitations of conventional drug delivery systems such as nonspecific biodistribution and targeting, lack of water solubility, low therapeutic indices, and poor oral bioavailability. Moreover, cancer nanotechnology has the potential of improving current approaches to cancer detection, diagnosis, and imaging. Recently, nanotechnology and molecular imaging have been combined to generate nanoparticles that simultaneously facilitate cancer therapy and diagnosis, the so called theragnostic nanoparticles. The aim of our review is to highlight recent developments within the context of the current knowledge of nanotechnology, to recall the experimental steps that have brought to the clinical development and application of nanoparticles, and explain the biological rationale for their use with oncologic patients. In particular, we summarize recent findings with respect to possible new applications for therapy and diagnosis, and their specific properties. Moreover, we report the more recent prospects in gene therapy, the possibility of using new drug delivery methods, the action of nanoparticles on the immune system and apoptosis, and the concrete possibility of detecting and characterizing circulating tumor cells or of developing new technologies in drug discovery.
Export Options
About this article
Cite this article as:
Allegra Alessandro, Penna Giuseppa, Alonci Andrea, Rizzo Vincenzo, Russo Sabina and Musolino Caterina, Nanoparticles in Oncology: The New Theragnostic Molecules, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (7) . https://dx.doi.org/10.2174/187152011796817682
DOI https://dx.doi.org/10.2174/187152011796817682 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Pilot Phase of the NIH Chemical Genomics Center
Current Topics in Medicinal Chemistry Advances in Drug Delivery Systems, from 0 to 3D superstructures
Current Drug Targets MtDNA As a Cancer Marker: A Finally Closed Chapter?
Current Genomics Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy In Vitro and In Vivo Investigations into the Carbene Gold Chloride and Thioglucoside Anticancer Drug Candidates NHC-AuCl and NHC-AuSR
Letters in Drug Design & Discovery Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics Strategies for Stalling Malignancy: Targeting Cancers Addiction to Hsp90
Current Topics in Medicinal Chemistry Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Dihidro-β-Agarofuran Sesquiterpenes: A New Class of Reversal Agents of the Multidrug Resistance Phenotype Mediated by P-Glycoprotein in the Protozoan Parasite Leishmania
Current Pharmaceutical Design Psychological Interventions for Parents of Children who have Cancer: A Meta-Analytic Review
Current Pediatric Reviews Recent Patents on Radiotherapy Bed
Recent Patents on Mechanical Engineering Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Topics in Medicinal Chemistry Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Vascular Endothelial Growth Factor (VEGF) in the Pathogenesis of Diabetic Nephropathy of Type 1 Diabetes Mellitus
Current Drug Targets Nanomaterials-based Polymerase Chain Reactions for DNA Detection
Current Organic Chemistry Applied Computational Techniques on Schizophrenia Using Genetic Mutations
Current Topics in Medicinal Chemistry Role of Sigma Receptors in Methamphetamine-Induced Neurotoxicity
Current Neuropharmacology